Literature DB >> 10366464

Laparoscopic lymphadenectomy for gynecologic malignancies.

P R Dottino1, D H Tobias, A Beddoe, A L Golden, C J Cohen.   

Abstract

OBJECTIVE: The purpose of our study was to detail our 5-year experience with laparoscopic lymphadenectomy for gynecologic malignancies.
METHODS: From 11/5/92 to 3/9/98, we performed laparoscopic lymphadenectomies on 94 patients with various gynecologic malignancies. Pelvic, paraaortic, and combinations of both pelvic and paraaortic lymphadenectomies were performed depending on the primary site of disease and indication for lymph node dissection. Data were prospectively collected on all patients.
RESULTS: From 11/5/92 to 3/9/98 we performed 94 laparoscopic lymphadenectomies for gynecologic malignancies. The distribution included 64 patients with cervical cancer, 14 with ovarian cancer, 12 with endometrial cancer, 2 with fallopian tube cancer, 1 with a uterine malignant mixed mesodermal tumor, and 1 with a metastatic neuroendocrine tumor. Fifty-five patients had only pelvic lymph node dissections, 9 patients had paraaortic dissections only, and 30 had both pelvic and paraaortic dissections performed. Among 30 patients having laparoscopic lymphadenectomy only, the mean hospital stay was 3.6 days. Included in this group were 19 patients who received postoperative neoadjuvant chemotherapy for cervical cancer as inpatients prior to ambulatory radiation therapy. The mean length of stay for this group was 4.6 days versus 1.7 days for the 11 patients who did not receive postoperative chemotherapy (P = 0.0025). The mean number of pelvic nodes was 11.9 (range 0-57), with a mean of 4. 5 between 11/5/92 and 12/31/95 and a mean of 19.1 from 1/1/96 to 3/9/98. The mean number of paraaortic nodes obtained was 3.7 (range 0-14), with a mean of 3.4 from 11/5/92 to 12/31/95 and a mean of 4.1 from 1/1/96 to 3/9/98. A total of 3 patients required conversions to laparotomy. One was for a vascular injury to the vena cava, 1 for a large tumor extending to both sidewalls, and the third for removal of densely matted lymph nodes.
CONCLUSIONS: Laparoscopic lymphadenectomy is a technically feasible procedure for patients with gynecologic malignancies requiring lymph node dissections, with an acceptable safety profile and nodal yield. The number of nodes obtained increased in direct proportion to operator experience. In addition, patients may benefit from a decrease in hospital stay compared to conventional lymphadenectomy via laparotomy. Copyright 1999 Academic Press.

Entities:  

Mesh:

Year:  1999        PMID: 10366464     DOI: 10.1006/gyno.1999.5376

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  6 in total

Review 1.  Innovative laparoscopic surgery in gynecologic oncology.

Authors:  Siobhan M Kehoe; Pedro T Ramirez; Nadeem R Abu-Rustum
Journal:  Curr Oncol Rep       Date:  2007-11       Impact factor: 5.075

Review 2.  Transperitoneal laparoscopic pelvic and paraaortic lymphadenectomy in gynecologic cancers.

Authors:  Siobhan M Kehoe; Nadeem R Abu-Rustum
Journal:  Curr Treat Options Oncol       Date:  2006-03

3.  Systemic Laparoscopic Para-Aortic Lymphadenectomy to the Left Renal Vein.

Authors:  Un Suk Jung; Joong Sub Choi; Jaeman Bae; Won Moo Lee; Jeong Min Eom
Journal:  JSLS       Date:  2019 Apr-Jun       Impact factor: 2.172

4.  The incidence of port-site metastases in gynecologic cancers.

Authors:  Nimesh P Nagarsheth; Jamal Rahaman; Carmel J Cohen; Herb Gretz; Farr Nezhat
Journal:  JSLS       Date:  2004 Apr-Jun       Impact factor: 2.172

5.  Introduction of robotic surgery for endometrial cancer into a Brazilian cancer service: a randomized trial evaluating perioperative clinical outcomes and costs.

Authors:  Alexandre Silva E Silva; João Paulo Mancusi de Carvalho; Cristina Anton; Rodrigo Pinto Fernandes; Edmund Chada Baracat; Jesus Paula Carvalho
Journal:  Clinics (Sao Paulo)       Date:  2018-09-21       Impact factor: 2.365

6.  Major vascular injury during gynecologic cancer surgery.

Authors:  Andrea L Buras; Jing Yi Chern; Hye Sook Chon; Mian M Shahzad; Robert M Wenham; Mitchel S Hoffman
Journal:  Gynecol Oncol Rep       Date:  2021-06-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.